O. Sagalova

发表

Clinical guidelines “Chronic diarrhea in adults”

L. Lazebnik, S. Turkina, E. Avalueva, 2021, Experimental and Clinical Gastroenterology.

Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2

M. Leshno, J. Mossong, C. Stedman, 2015, Journal of viral hepatitis.

[Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis].

I. Maev, V. Ivashkin, V. Chulanov, 2021, Terapevticheskii arkhiv.

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.

W. Haefeli, M. Haag, U. Merle, 2022, The Lancet. Infectious diseases.

Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

M. Leshno, J. Mossong, C. Stedman, 2015, Journal of viral hepatitis.

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Gamal Esmat, Rui Tato Marinho, Mel Krajden, 2017, The lancet. Gastroenterology & hepatology.

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

M. Buti, R. Marinho, K. Simon, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.

S. Alavian, R. Malekzadeh, V. Wong, 2018, The lancet. Gastroenterology & hepatology.

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.

Jisoo A. Kwon, V. Wong, F. Tacke, 2022, The lancet. Gastroenterology & hepatology.

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2

M. Leshno, J. Mossong, C. Stedman, 2015, Journal of viral hepatitis.

Modes of antiviral therapy containing daclatasvir, when mixed cryoglobulinemia associated with chronic infection with hepatitis C virus (multicentre study in the framework of individual access)

V. Ivashkin, I. Bakulin, O. Sagalova, 2018, Clinical Medicine (Russian Journal).

Persistent mixed cryoglobulinemia after successful antiviral treatment of chronic hepatitis C virus infection: What's the next?

V. Ivashkin, I. Bakulin, O. Sagalova, 2018, Scandinavian journal of gastroenterology.

P1285 : Forecasting the disease burden of chronic hepatitis C in Russia

H. Razavi, V. Chulanov, K. Razavi-Shearer, 2015 .

Hospital-based surveillance of rotavirus and other viral agents of diarrhea in children and adults in Russia, 2005-2007.

R. Glass, J. Vinjé, U. Parashar, 2009, The Journal of infectious diseases.

[Chronic hepatitis C in Russia: current challenges and prospects].

V. Chulanov, O. Sagalova, I. Shestakova, 2015, Terapevticheskii arkhiv.

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.

A. Berger, S. Ciesek, P. Lampertico, 2023, The New England journal of medicine.

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

S. Zeuzem, P. Lampertico, H. Wedemeyer, 2022, Journal of Hepatology.

Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

M. Buti, R. Gish, P. Lampertico, 2022, Journal of Hepatology.

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

M. Buti, M. Biermer, T. Asselah, 2023, The Lancet Gastroenterology & Hepatology.

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.

S. Alavian, R. Malekzadeh, V. Wong, 2018, The lancet. Gastroenterology & hepatology.

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.

Jisoo A. Kwon, R. Malekzadeh, F. Tacke, 2023, The lancet. Gastroenterology & hepatology.

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

S. Alavian, M. Manns, Chien-Jen Chen, 2017, The lancet. Gastroenterology & hepatology.

Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results from a Phase 3 Randomized, Multicenter, Parallel Design Study

S. Zeuzem, P. Lampertico, H. Wedemeyer, 2023, 39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber.

Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.

G. Gherlan, M. Hilleret, V. Pântea, 2024, The New England journal of medicine.

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial.

O. Sagalova, D. Manuilov, N. Mamonova, 2024, Journal of hepatology.